Clinical Trials Service

 

 

Home


Team Members


Patient Information


Clinical Trials


Basic Research

 

Fellowship Program
 
Images of Omaha



Contact Us:

Division of Allergy and Immunology
CreightonUniversity
601 North 30th Street, Suite 3M-100
Omaha,NE 68131
 
 

Ph.402.280.5975
Fx.402.280.5961
Email

                                                                              

The Center is conducting the following new and exciting studies.

If you or someone you know is eligible and interested,

we would love to hear from you. 

Please call (402) 280-5975.

 

Patient Demographics

      The Omaha area has a population of over 750,000. The Division’s clinical research patient database alone is currently comprised of over 5,000 patients and is constantly growing through the various recruitment efforts including media advertising, health fair involvement as well as volunteer work. Our diverse patient population is drawn not only from the Omaha metropolitan area (urban/suburban), but also from the surrounding communities in Eastern Nebraska and Western Iowa (rural).

Areas of Research

Acute and chronic otitis media

Acute and chronic urticaria

Acute sinusitis

Allergic asthma

Allergic bronchopulmonary aspergillosis

Allergic conjunctivitis

Angioedema

Asthma in pregnancy

B cell immunodeficiencies

Bronchitis

Common variable immunodeficiency

Contact dermatitis

Drug allergy

Exercise induced asthma

Food allergy and food hypersensitivity

Immunizations and immunoprophylaxis

Insect allergy

Latex allergy

Management of immunotherapy

Non-allergic asthma

Nasal polyposis

 Perennial allergic rhinitis

 Seasonal allergic rhinitis

 Status asthmaticus

 T-cell immunodeficiencies

 Vasomotor rhinitis

 Urticaria

 

     The Division of Allergy and Immunology has a three bed inpatient unit suitable for Phase I and Phase II studies.  The Division conducts first-in-man studies and has several model systems for proof of concept trials for allergic and respiratory diseases. In addition, the basic research laboratories of the Division are capable of assisting in clinical trials with the measurement of biomarkers and mechanistic assays. 

Procedures and Equipment Available    

 

                                       

Acoustic Rhinometry

Aeroallergen challenge

Exercise challenge

Hypertonic Saline challenge

Methacholine challenge

Bronchoprovocation Challenges

Biomarker Assays (Interleukins/Cytokines, Leukotrienes, Histamine, Tryptase, ECP)                 

Digital Electrocardiography Machine

Full Pulmonary Function Laboratory

Immediate and Delayed Hypersensitivity Skin Testing

Immunotherapy

Inpatient Beds

Nasal Allergen Challenges and Lavage

Nitric Oxide Measurements (oral/nasal)

Oral Desensitization

Parenteral Therapy Facilities

Phlebotomy

Pollen Collection

Radiology Suite for Routine X-Rays, MRIs ,CTs, Nuclear Studies

Remote Data Entry Capabilities

Spirometry

Sputum Induction

Treadmill Exercise Testing

 

Investigators

Thomas B. Casale, M.D.
Professor of Medicine and Medical Microbiology & Immunology; Chief, Division of Allergy & Immunology Bio

Robert G. Townley, M.D.
Professor of Medicine and Medical Microbiology & Immunology Bio
Againdra K. Bewtra, M.B.B.S., M.D.
Associate Professor of Medicine & Biomedical Sciences Bio

Jeffrey R. Stokes, M.D.

Associate Professor of Medicine, Fellowship Program Director, Fellowship Program     Bio

Russell J. Hopp, D.O.
Professor of Pediatrics and Medicine; Chief, Division of Pediatric Allergy & Clinical Immunology
Bio

 

 Staff

  Patrick De Nier:  Operations Manager

Tony Tony Romero, MS:  Budget, Contracts, & Regulatory Documents

Dian Jean Kessler, RN, BSN, CCRC:  Research Coordinator

Lori   Lori Mahon, RN, BSN,CCRC: Research Coordinator

Jani  Janie Misfieldt, MA, CCRC:  Research Coordinator

Jean Renee Smith, CMA:  Research Coordinator

 

 

 Current Clinical Trials        

  • Exhaled Breath Condensate and Nitric Oxide:  Non-Invasive Evaluation of Lung Disease after Treatment with Xolair in subjects with Allergic Asthma, 12 years and older.
  • Randomized, Double-Blind, Double-Dummy, Placebo and Active Controlled 5-Way Crossover Study to Assess the Bronchodilatory Action, Safety, Toleration and Pharmacokinetics of Single Oral Doses of PF-04191834 in Asthmatic Patients, 19 years and older.
  • Relationship of RGS2 and RhOA Expression and Airway Hyperresponsiveness, 19 years and older.
  • A 12-week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 ug o.d.), 12 years and older.
  • A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab in Adult Patients with Asthma who are Inadequately Controlled on Inhaled Corticosteroids.
  • A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults with Uncontrolled Asthma, 19-65 years old
  • A 52-week Treatment, Randomized, Double-Blind, Placebo-Controlled, with Open Label Tiotropium, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 in Patients with Chronic Obstructive Pulmonary Disease, 19 years and older.
  • A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed Sublingual Tablet (SCH 39641) in Adult Subjects with a History of Ragweed-Induced Rhinoconjunctivitis with or without Asthma, 19-50 years old.

 

 

 

 

Home| Team Members | Patient Information |
Current Clinical Trials | Fellowship Program